Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Anti-racism Position Statement

Speech Pathology Australia (Mok, Z part of contributing authors)

(2023)

Laryngectomy Practice Guideline

Speech Pathology Australia (Manoharan, M part of contributing author group)

(2023)

Risk of kidney disease following a pregnancy complicated by diabetes: a longitudinal, population-based data-linkage study among Aboriginal women in the Northern Territory, Australia.

Matthew J L Hare, Louise J Maple-Brown, Jonathan E Shaw, Jacqueline A Boyle, Paul D Lawton, Elizabeth L M Barr, Steven Guthridge, Vanya Webster, Denella Hampton, Gurmeet Singh, Roland F Dyck, Federica Barzi

(2023), Diabetologia, 66(5), 837-846

DOI: 10.1007/s00125-023-05868-w

Electronic alerts and a care bundle for acute kidney injury - an Australian cohort study

Kotwal S, Herath S, Erlich J, Boardman S, Qian J, Lawton P, Campbell C, Whatnall A, Teo S, Horvath AR, Endre ZH

(2023), NEPHROLOGY DIALYSIS TRANSPLANTATION, 38(3), 610-7

DOI: 10.1093/ndt/gfac155

Surgery for maxillary oral squamous cell carcinoma: the effect of surgical resection margins and elective neck dissection on oncological outcomes.

Woo S, DeAngelis A, Koo K, Kranz S, Nastri A, Iseli TA, Fua T, Wiesenfeld D

(2023), International journal of oral and maxillofacial surgery, 52(3), 283-90

DOI: 10.1016/j.ijom.2022.06.015

Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry

Wei, Gavin; Ranasinghe, Weranja Kalana Bodhisiri; Evans, Melanie Alice; Bolton, Damien Michael; Dodds, Lachlan J.; Frydenberg, Mark; Kearns, Paul A.; Lawrentschuk, Nathan; Murphy, Declan G.; Millar, Jeremy Laurence; Papa, Nathan Paul

(2023), BJU International, 131, 36-42

DOI: 10.1111/bju.15980

Outcomes after PD-103 versus I-125 for Low Dose Rate Prostate Brachytherapy Monotherapy: An International, Multi-Institutional Study

Tang C, Sanders J, Thames H, Swanson DM, Crook JM, Bruno T, Blanchgard P, Ciezki J, Keyes M, Song D, Singh T, Merrick G, Stock R, Sullivan FJ, Mok H, Millar J, Frank S

(2023), Radiotherapy and Oncology, 183, 109599

DOI: 10.1016/j.radonc.2023.109599

Effects of synchrotron-based X-rays and gold nanoparticles on normal and cancer cell morphology and migration

Shahhoseini E, Nakayama M, Panettieri V, Hall C, Feltis B, Geso M

(2023), Journal of Synchrotron Radiation, 30(2), 359-367

DOI: 10.1107/S1600577522012024

Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label

Semsarian CR, Ma T, Nickel B, Barratt A, Varma M, Delahunt B, Millar J, Parker L, Glasziou P, Bell K

(2023), PROSTATE, 83(6), 498-515

DOI: 10.1002/pros.24493

Modern Active Surveillance in Prostate Cancer

Pattenden, Trent A.; Samaranayke, Dhanika; Morton, Andrew; Ong, Wee Loon; Murphy, Declan G.; Pritchard, Elizabeth Kathleen; Evans, Susan Margaret; Millar, Jeremy Laurence; Chalasani, Venu; Rashid, Prem; Winter, Matthew W.; Vela, Ian; Pryor, David I.; Mark

(2023), Clinical Genitourinary Cancer, 21, 115-123

DOI: 10.1016/j.clgc.2022.09.003

To boost or not to boost - pooled analyses from two-fraction stereotactic ablative radiotherapy (SABR) trials for localised prostate cancer

Ong, WL, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

(2023), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 117(5), 1153-62

DOI: 10.1016/j.ijrobp.2023.06.250

Response to comment to “Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer”

Ong, Wee Loon; Zhang, Liying; Loblaw, Andrew

(2023), Radiotherapy and oncology, 189

DOI: 10.1016/j.radonc.2023.109918

Large variation in radiation therapy fractionation for multiple myeloma in Australia

Ong, Wee Loon; MacManus, Michael Patrick; Milne, Roger; Foroudi, Farshad; Millar, Jeremy Laurence

(2023), Asia-Pacific Journal of Clinical Oncology, 19, 149-157

DOI: 10.1111/ajco.13783

Stereotactic Body Radiation Therapy for Spine Metastases—Findings from an Australian Population-Based Study.

Ong WL, Milne RL, Foroudi F, Millar JL

(2023), Current Oncology, 30(8), 7777-7788

DOI: 10.3390/curroncol30080564

The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer - Quo Vadimus

Ong WL, Loblaw A

(2023), World Journal of Urology, 41(12), 3485-91

DOI: 10.1007/s00345-023-04663-x

Urethra delineation based on computed tomography urethrogram versus magnetic resonance imaging in prostate stereotactic ablative body radiotherapy

Ong WL, Hupman A, Davidson M, Detsky J, Liu S, Vesprini D, Loblaw A

(2023), CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 45, 100722

DOI: 10.1016/j.ctro.2023.100722

Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer

Ong WL, Evans M, Papa N, Williams S, Millar J

(2023), JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 67(7), 789-95

DOI: 10.1111/1754-9485.13596

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer

Ong WL, Davidson M, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng C, Vesprini D, Ravi A, McGuffin M, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

(2023), Radiotherapy and Oncology, 188, 109864

DOI: 10.1016/j.radonc.2023.109864

Predictors for late genitourinary toxicity in men receiving radiotherapy for high-risk prostate cancer using planned and accumulated dose

Ong ALK, Knight K, Panettieri V, Dimmock M, Tuan JKL, Tan HQ, Wright C

(2023), Physics & Imaging in Radiation Oncology, 25(6), 100421

DOI: 10.1016/j.phro.2023.100421

Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study

O'Callaghan ME, Roberts MJ, Moretti KL, Frydenberg M, Gilbourd D, Mark S, Heathcote P, Millar J, Pcor-Anz, Papa N

(2023), UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 41(2), 105.e-105.e18

DOI: 10.1016/j.urolonc.2022.10.020

1 2 3